Nature Communications (Jun 2024)

Retrotransposons in Werner syndrome-derived macrophages trigger type I interferon-dependent inflammation in an atherosclerosis model

  • Sudip Kumar Paul,
  • Motohiko Oshima,
  • Ashwini Patil,
  • Masamitsu Sone,
  • Hisaya Kato,
  • Yoshiro Maezawa,
  • Hiyori Kaneko,
  • Masaki Fukuyo,
  • Bahityar Rahmutulla,
  • Yasuo Ouchi,
  • Kyoko Tsujimura,
  • Mahito Nakanishi,
  • Atsushi Kaneda,
  • Atsushi Iwama,
  • Koutaro Yokote,
  • Koji Eto,
  • Naoya Takayama

DOI
https://doi.org/10.1038/s41467-024-48663-w
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 17

Abstract

Read online

Abstract The underlying mechanisms of atherosclerosis, the second leading cause of death among Werner syndrome (WS) patients, are not fully understood. Here, we establish an in vitro co-culture system using macrophages (iMφs), vascular endothelial cells (iVECs), and vascular smooth muscle cells (iVSMCs) derived from induced pluripotent stem cells. In co-culture, WS-iMφs induces endothelial dysfunction in WS-iVECs and characteristics of the synthetic phenotype in WS-iVSMCs. Transcriptomics and open chromatin analysis reveal accelerated activation of type I interferon signaling and reduced chromatin accessibility of several transcriptional binding sites required for cellular homeostasis in WS-iMφs. Furthermore, the H3K9me3 levels show an inverse correlation with retrotransposable elements, and retrotransposable element-derived double-stranded RNA activates the DExH-box helicase 58 (DHX58)-dependent cytoplasmic RNA sensing pathway in WS-iMφs. Conversely, silencing type I interferon signaling in WS-iMφs rescues cell proliferation and suppresses cellular senescence and inflammation. These findings suggest that Mφ-specific inhibition of type I interferon signaling could be targeted to treat atherosclerosis in WS patients.